• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Allogene Therapeutics, Inc. - Common Stock (NQ:ALLO)

1.710 +0.220 (+14.77%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 12,310,494
Open 1.660
Bid (Size) 1.680 (500)
Ask (Size) 1.730 (700)
Prev. Close 1.490
Today's Range 1.660 - 1.880
52wk Range 0.8621 - 3.780
Shares Outstanding 142,183,418
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The market is filled with gapping stocks in Friday's session. ↗
January 09, 2026
Via Chartmill
News headline image
Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T
January 08, 2026
From Allogene Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+26.7%
+26.7%
1 Month
+10.3%
+10.3%
3 Month
+34.6%
+34.6%
6 Month
+32.6%
+32.6%
1 Year
-16.8%
-16.8%

More News

Read More
News headline image
Billionaire Family Office Dumps All of Its UroGen Stock Amid 100% Rally ↗
December 26, 2025
Via The Motley Fool
Topics Death Regulatory Compliance
News headline image
Earnings Scheduled For November 6, 2025 ↗
November 06, 2025
Via Benzinga
News headline image
What a Billionaire Family Office's $16.6 Million Exit From TIC Solutions Signals for Long-Term Investors ↗
December 26, 2025
Via The Motley Fool
Topics Death Regulatory Compliance
News headline image
Allogene Arbitration Victory Pressures Cellectis Shares Tuesday ↗
December 16, 2025
Via Benzinga
News headline image
Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis
December 15, 2025
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
The Unseen Hand: Congressional Leaders Under Fire for Alleged Stock Market Outperformance
December 04, 2025
Via MarketMinute
Topics Bonds ETFs World Trade
News headline image
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
November 10, 2025
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Inc (NASDAQ:ALLO) Reports Q3 2025 Earnings Beat and Pipeline Progress ↗
November 06, 2025
Via Chartmill
Topics Earnings
News headline image
Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update
November 06, 2025
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting
November 03, 2025
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update
October 30, 2025
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Adaptimmune Plunges After Announcing Nasdaq Delisting Amidst Compliance Failures and Cost-Cutting Measures
October 20, 2025
Via MarketMinute
Topics Initial Public Offering Regulatory Compliance Workforce
News headline image
This Keysight Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday ↗
October 10, 2025
Via Benzinga
News headline image
Allogene Therapeutics Announces Participation in Upcoming Investor Conference
August 27, 2025
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Allogene Q2 Cash Tops $300 Million ↗
August 13, 2025
Via The Motley Fool
News headline image
Allogene Narrows Loss in Fiscal Q2 ↗
August 13, 2025
Via The Motley Fool
News headline image
Allogene Therapeutics Inc (NASDAQ:ALLO) Reports Narrower-Than-Expected Q2 2025 Loss, Shares Rise Modestly ↗
August 13, 2025
Via Chartmill
News headline image
Allogene Therapeutics Reports Second Quarter 2025 Financial Results and Business Update
August 13, 2025
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For August 13, 2025 ↗
August 13, 2025
Via Benzinga
News headline image
A Look at Allogene Therapeutics's Upcoming Earnings Report ↗
August 12, 2025
Via Benzinga
News headline image
Allogene Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update
August 06, 2025
From Allogene Therapeutics, Inc.
Via GlobeNewswire
News headline image
This AvalonBay Communities Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Monday ↗
August 04, 2025
Via Benzinga
News headline image
Allogene Resets Clinical Course After Patient Death In Lymphoma Study ↗
August 01, 2025
Via Benzinga

Frequently Asked Questions

Is Allogene Therapeutics, Inc. - Common Stock publicly traded?
Yes, Allogene Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Allogene Therapeutics, Inc. - Common Stock trade on?
Allogene Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Allogene Therapeutics, Inc. - Common Stock?
The ticker symbol for Allogene Therapeutics, Inc. - Common Stock is ALLO on the Nasdaq Stock Market
What is the current price of Allogene Therapeutics, Inc. - Common Stock?
The current price of Allogene Therapeutics, Inc. - Common Stock is 1.710
When was Allogene Therapeutics, Inc. - Common Stock last traded?
The last trade of Allogene Therapeutics, Inc. - Common Stock was at 01/09/26 04:00 PM ET
What is the market capitalization of Allogene Therapeutics, Inc. - Common Stock?
The market capitalization of Allogene Therapeutics, Inc. - Common Stock is 243.13M
How many shares of Allogene Therapeutics, Inc. - Common Stock are outstanding?
Allogene Therapeutics, Inc. - Common Stock has 243M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap